Skin of colour is still too often approached as a variation in appearance rather than a variation in function; that distinction is not semantic. It determines how the skin behaves under stress, how it responds to treatment, and why outcomes are often less predictable when the underlying biology has not been properly considered. Pigmentation is usually the feature that draws attention, but it is only one part of a broader system involving barrier integrity, lipid organisation, hydration dynamics, dermal architecture, and melanocyte activity.
What is often not recognised is that many of the complications seen in skin of colour are not the result of inherently “difficult” skin, but of inappropriate frameworks being applied to it. Treatments that are considered routine in lighter Fitzpatrick skin types are frequently extrapolated without sufficient adjustment, and the resulting outcomes are then attributed to the patient rather than the approach.
In practice, this presents consistently. Patients report worsening pigmentation after facials, peels, or laser treatments that were intended to improve their skin. Others describe cycles of improvement followed by relapse, often after introducing new skincare or undergoing repeated procedures. The underlying issue is rarely a single treatment decision. It is a failure to recognise that the biology of the skin requires a different level of restraint, sequencing, and precision.
Understanding physiology therefore moves beyond academic interest. It becomes the basis for avoiding harm as much as achieving improvement.
Barrier dynamics and skincare sensitivity
The epidermal barrier (stratum corneum) is the most immediate interface between the skin and its environment, yet it is frequently described in overly static terms. In practice, it is a dynamic structure that regulates water movement, modulates inflammatory signalling, and determines how the skin interacts with topical products and procedural interventions.
Transepidermal water loss remains one of the most commonly used measures of barrier function, reflecting the passive diffusion of water through the stratum corneum. The literature comparing transepidermal water loss across different ethnic groups is inconsistent, with studies reporting both increased and reduced values in darker skin relative to lighter skin. That inconsistency is not a limitation so much as a reflection of variability within populations and the influence of environmental and methodological factors. Where transepidermal water loss is elevated, however, the implication is consistent: the barrier is more easily disrupted and less effective at maintaining hydration. Clinically, this corresponds with the experience many patients describe, where the skin appears structurally robust but behaves in a way that is easily irritated.
This behaviour becomes more intelligible when the structure and composition of the stratum corneum are considered in more detail. Skin of colour typically has a more compact stratum corneum with a greater number of corneocytes (skin cells), often cited at around twenty compared with approximately sixteen in lighter skin types. This increased density might be expected to confer greater resilience, yet barrier function depends less on thickness than on the organisation of intercellular lipids. Total lipid content may be higher, but ceramide levels have been reported as significantly lower, in some studies by up to fifty per cent compared with Caucasian and Hispanic skin. The ratio between ceramides, cholesterol, and free fatty acids is also altered, and these components must exist in a precise arrangement to maintain barrier integrity. When that arrangement is disrupted, permeability increases despite the presence of a thicker outer layer. Increased natural shedding of skin cells (desquamation) further complicates this, with corneocyte cell shedding reported to be up to two and a half times higher in African American skin. The result is a barrier that is structurally dense yet functionally more labile, particularly when exposed to repeated external stress.
What is often underestimated in clinical practice is how easily this balance is disrupted by well-intentioned skincare. Patients with skin of colour are disproportionately likely to be using multiple active ingredients simultaneously, often introduced without a clear understanding of barrier tolerance. Acids, retinoids, exfoliating toners, and “brightening” products are layered in an attempt to address pigmentation or texture, yet in doing so, they create a low-grade, persistent disruption of the barrier.
This is one of the reasons why simplifying skincare often produces more improvement than adding further intervention. Stability, rather than intensity, becomes the prerequisite for successful treatment.
Hydration, thermal response, and procedural considerations
Hydration interacts with these processes in a way that is often underestimated. Electrical conductance measurements, which correlate with water content, have demonstrated higher conductance in African American and Hispanic skin compared with Caucasian skin, indicating greater epidermal hydration. While this might be interpreted as a favourable characteristic, it has practical implications. Water facilitates the conduction and retention of heat, which becomes relevant when treatments rely on thermal mechanisms. The same energy delivered to skin with differing water content does not behave identically, and this is one of the reasons why standardised laser treatment parameters can produce variable results across skin types. In clinical terms, this reinforces the need to adjust not only the choice of treatment but how it is delivered.
This variability in thermal behaviour has practical consequences that are frequently overlooked. Many devices are marketed as being suitable for all skin types, and in principle this may be true. However, safety does not equate to uniformity of response. The same settings applied across different patients can result in under-treatment in some and excessive thermal accumulation in others.
In skin of colour, where both hydration and melanocyte responsiveness influence outcome, this margin for error becomes narrower. It is not simply a question of avoiding burns or overt complications. Subclinical inflammation, even when not immediately visible, can be sufficient to trigger pigmentation. This is why, for example, conservative laser parameter selection is often appropriate, but it is only part of the solution. Treatment design must also consider cumulative exposure. Repeated sessions, even when individually well tolerated, can create a threshold effect where inflammation becomes clinically apparent only after several treatments. Without careful spacing and reassessment, this can lead to delayed complications that are incorrectly attributed to a single session rather than the overall treatment strategy.
The deeper layer of the skin, the dermis, introduces further distinctions that are less immediately apparent but equally influential. In darker skin, the dermis is typically thicker, with collagen fibres arranged in smaller, tightly packed bundles and embedded within a more complex ground substance. The dermoepidermal junction (the junction between the upper and lower layers) is more convoluted, increasing the interface or surface area between layers and contributing to structural cohesion. There is also evidence of increased fibroblast density and a more developed lymphatic network. These features contribute to the observation that skin of colour demonstrates a slower progression of visible ageing, with fewer fine lines and a reduced degree of photodamage at a given age.
Photobiological data support this, with darker skin demonstrating greater intrinsic protection against ultraviolet radiation. Estimates place the intrinsic UVB protection factor of darker skin at approximately 13.4 compared with around 3.4 in lighter skin, with a corresponding reduction in ultraviolet penetration. Protection against UVA is also greater, although incomplete, and studies have shown that substantially less ultraviolet radiation reaches the dermis in darker skin compared with lighter skin.
Melanocyte activity and pigmentation management
This intrinsic protection is clinically relevant but often misinterpreted. It reduces the likelihood of acute ultraviolet injury but does not eliminate the effects of light on the skin. Pigmentary disorders remain common, and the role of light extends beyond ultraviolet wavelengths.
The cells that produce pigment in the skin, called melanocytes, are not just passive. In terms of skin colour, they are more active and produce larger packets of pigment, which are spread more widely throughout the skin. They are also more sensitive, meaning they respond quickly to irritation or inflammation. This responsiveness is central to understanding post-inflammatory hyperpigmentation. The trigger may be relatively minor, including acne, eczema, friction, or barrier disruption from inappropriate skincare, yet the resulting pigmentation can be pronounced and persistent. The relationship between the initial insult and the visible pigment is often disproportionate, reflecting the sensitivity of melanocytes to even low levels of inflammation.
An additional layer of complexity arises from the persistence of pigment once it has been formed. In many patients, the rate of pigment clearance does not match the rate of pigment production. Even when the initial trigger has resolved, residual pigmentation may remain for months or longer, particularly if the skin continues to be exposed to low-level inflammatory or environmental stimuli.
This has important implications for treatment expectations. Patients often seek rapid correction, particularly when pigmentation follows an identifiable event such as acne or a procedure. However, the biological processes involved do not operate on the same timeline as visible change. Attempting to accelerate clearance through more aggressive intervention frequently reintroduces inflammation and perpetuates the cycle.
A more effective approach involves reducing ongoing triggers, supporting barrier function, and using targeted pigment modulation in a controlled manner. This may appear slower, but it is more consistent with the biology of the skin and reduces the risk of rebound pigmentation
Approaching pigmentation effectively therefore requires attention to both melanogenesis and its triggers. Tyrosinase remains the key enzyme in melanin synthesis, and inhibitors such as hydroquinone reduce pigment by targeting this pathway. Deoxyarbutin operates through a similar mechanism. Tranexamic acid represents a different approach, acting indirectly by reducing the release of inflammatory mediators that stimulate melanocytes. These differences are clinically meaningful, as they reflect the multiple pathways involved in pigment production. Combining agents that act through different mechanisms often produces more stable results than relying on a single intervention, particularly when treatment is combined with measures that reduce ongoing inflammation.
Light exposure remains one of the most significant external drivers of pigmentation, and its role extends beyond ultraviolet radiation. Visible light has been shown to contribute to pigmentation in darker skin, particularly in conditions such as melasma. Unlike ultraviolet radiation, which is partially mitigated by melanin, visible light penetrates differently and can stimulate melanocytes through alternative pathways. This has implications for photoprotection. Standard sunscreens are designed primarily to block ultraviolet radiation, but they do not fully address visible light. Inorganic filters such as zinc oxide and titanium dioxide reflect ultraviolet light, but their effectiveness against visible light depends on formulation. The inclusion of iron oxides, which provide pigment to tinted sunscreens, allows for protection against visible light and is therefore an important component of managing dyschromia in skin of colour. The use of tinted sunscreen is not simply cosmetic. It reflects the need to address a broader spectrum of light exposure.
A further point that is often overlooked is that light exposure in daily life is cumulative and not limited to direct sun exposure. Patients frequently assume that pigmentation is driven primarily by periods of intense ultraviolet exposure, such as holidays or outdoor activity. In reality, lower-level, repeated exposure to visible light, including indoor lighting and screen exposure, may contribute to persistent stimulation of melanocytes over time.
While the magnitude of this effect varies, it helps explain why pigmentation can remain resistant to treatment despite what appears to be adequate sun protection. In many cases, the issue is not the absence of protection but the mismatch between the type of protection used and the wavelengths that are driving pigmentation.
This reinforces the importance of consistency. Photoprotection is not a seasonal intervention, nor is it limited to periods of high ultraviolet index. In patients prone to pigmentation, it becomes part of daily barrier management, alongside skincare and treatment planning. When applied consistently and appropriately, it reduces one of the most persistent external drivers of melanocyte activity.
Precision, sequencing, and sustainable treatment outcomes
When these physiological differences are considered together, the limitations of a standardised approach become apparent. Skin of colour cannot be managed effectively using protocols developed for lighter skin with minor adjustments. The barrier is more reactive, lipid composition differs, hydration influences thermal behaviour, the dermis responds differently to injury, and melanocytes are more readily stimulated by inflammation. These factors interact in ways that influence how the skin responds to both topical and procedural treatments. Interventions that rely on controlled injury must therefore be applied with precision, and the cumulative effect of repeated treatments must be considered.
In practice, this shifts the emphasis away from rapid correction towards maintaining stability within the skin. Preserving barrier integrity, minimising unnecessary inflammation, and selecting treatments that align with the underlying biology become central considerations. This approach may appear more measured, but it is more consistent with how the skin behaves and is more likely to produce outcomes that are both effective and sustainable. Attempts to accelerate improvement through more aggressive intervention often introduce additional instability, particularly in patients who are already prone to pigmentation.
Variation in outcomes between clinics is often attributed to differences in products or devices, but this explanation is incomplete. Devices and formulations operate within defined parameters, yet the way those parameters are applied depends on the clinician’s understanding of the skin. The same treatment can produce very different results depending on how carefully these variables are managed. For patients with darker skin, the more relevant question is not which treatment is being used, but whether the approach reflects an understanding of how their skin behaves.
A common question in clinical practice is why treatments that appear successful in one individual produce complications in another. The answer lies not in the device itself, but in the interaction between the treatment and the underlying physiology of the skin. In terms of skin colour, this interaction is less forgiving. Small deviations in energy delivery, product selection, or treatment timing can produce disproportionately large effects. What might be a minor inflammatory response in lighter skin can translate into clinically significant pigmentation in darker skin.
This is particularly relevant in the context of combination treatments. While combining modalities can be effective, it also increases the cumulative inflammatory burden. Without careful sequencing and sufficient recovery time, the risk of unintended outcomes increases. The principle is not to avoid combination therapy, but to apply it with a level of restraint and precision that reflects the biological response of the skin.
At Self London, this forms the basis of assessment and treatment planning. The visible concern is considered alongside barrier function, inflammatory tendency, and pigment response, and treatment is structured accordingly. This is why interventions are often sequenced differently and spaced more deliberately than patients might expect. The objective is not simply to produce visible change, but to do so in a way that the skin can sustain without further disruption. Over time, this approach tends to produce more consistent outcomes and reduces the likelihood of creating new concerns while attempting to address existing ones.
Skin of colour does not require a fundamentally different set of tools, but it does require a different level of precision in how those tools are used. Its behaviour reflects a complex interaction between structure and response, and when that interaction is understood, treatment becomes more predictable. When it is not, complications are often the result of applying a simplified approach to a system that does not respond well to simplification.
